Immune Changes in Breast Cancer Patients Undergoing Taxane Chemotherapy
Author Information
Author(s): Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D
Primary Institution: Laikon General Hospital, Athens University School of Medicine
Hypothesis
The study aims to evaluate the effect of taxanes (paclitaxel and docetaxel) on immunological parameters in breast cancer patients.
Conclusion
Both paclitaxel and docetaxel increase certain immune parameters in breast cancer patients while decreasing others, with docetaxel showing a more pronounced effect.
Supporting Evidence
- All patients in both groups responded to therapy.
- Significant differences were observed in immune parameters between the control group and pretreatment values of both taxane groups.
- Docetaxel demonstrated a more pronounced effect on enhancing immune parameters compared to paclitaxel.
Takeaway
This study shows that chemotherapy with paclitaxel or docetaxel helps boost the immune system in women with advanced breast cancer.
Methodology
Thirty women with advanced breast cancer were randomly assigned to receive either paclitaxel or docetaxel, and various immune parameters were measured before and after treatment.
Potential Biases
Potential bias due to the small sample size and lack of a control group receiving no treatment.
Limitations
The study only included women with advanced breast cancer and did not assess long-term immune changes post-treatment.
Participant Demographics
Thirty women with advanced breast cancer, age and performance status were balanced between treatment groups.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website